Loading
A phase 2 trial of Disitamab vedotin, Toripalimab, Carboplatin and Epirubicin in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer is a phase 2 interventional study registered as NCT06227117 by RemeGen Co., Ltd., with 120 participants planned, started 2023-07-27 and due to reach its primary completion in 2025-12. Interventions recorded: Disitamab Vedotin Injection （18 weeks）, Toripalimab （18weeks）, Carboplatin, Disitamab Vedotin Injection （12 weeks）, Sequential Epirubicin and Sequential CTX.
Shares RemeGen, Disitamab vedotin, Epirubicin, Toripalimab and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Toripalimab, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Carboplatin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC) and the tag pipeline.
Shares RemeGen, Disitamab vedotin, Antibody-drug conjugate (ADC), Immune checkpoint inhibitors and the tag pipeline.